Jared M Baeten1, Thesla Palanee-Phillips2, Nyaradzo M Mgodi3, Ashley J Mayo4, Daniel W Szydlo5, Gita Ramjee6, Brenda Gati Mirembe7, Felix Mhlanga3, Portia Hunidzarira3, Leila E Mansoor8, Samantha Siva9, Vaneshree Govender6, Bonus Makanani10, Logashvari Naidoo9, Nishanta Singh9, Gonasagrie Nair11, Lameck Chinula12, Urvi M Parikh13, John W Mellors13, Iván C Balán14, Kenneth Ngure15, Ariane van der Straten16, Rachel Scheckter4, Morgan Garcia4, Melissa Peda5, Karen Patterson5, Edward Livant17, Katherine Bunge18, Devika Singh17, Cindy Jacobson17, Yuqing Jiao5, Craig W Hendrix19, Zvavahera M Chirenje3, Clemensia Nakabiito7, Taha E Taha20, Judith Jones17, Kristine Torjesen4, Annalene Nel21, Zeda Rosenberg21, Lydia E Soto-Torres22, Sharon L Hillier18, Elizabeth R Brown23. 1. Department of Global Health, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA. Electronic address: jbaeten@uw.edu. 2. Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 3. University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe. 4. FHI 360, Durham, NC, USA. 5. Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 6. HIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa; Aurum Institute, Johannesburg, South Africa. 7. Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda. 8. Centre for AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa. 9. HIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa. 10. College of Medicine-Johns Hopkins Research Project, Queen Elizabeth Central Hospital, Blantyre, Malawi. 11. The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa. 12. University of North Carolina Project, Lilongwe, Malawi; Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA. 13. Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 14. HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia University, New York, NY, USA. 15. Department of Community Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya. 16. Women's Global Health Imperative, RTI International, San Francisco, CA, USA; Center for AIDS Prevention Studies, Department of Medicine, University of California San Francisco, San Francisco, CA, USA. 17. Magee-Womens Research Institute, Pittsburgh, PA, USA. 18. Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA, USA. 19. Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 20. College of Medicine-Johns Hopkins Research Project, Queen Elizabeth Central Hospital, Blantyre, Malawi; Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA. 21. International Partnership for Microbicides, Silver Spring, MD, USA. 22. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 23. Department of Biostatistics, University of Washington, Seattle, WA, USA; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Abstract
BACKGROUND: Two phase 3 clinical trials showed that use of a monthly vaginal ring containing 25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by approximately 30% compared with placebo. We aimed to evaluate use and safety of the dapivirine vaginal ring (DVR) in open-label settings with high background rates of HIV-1 infection, an important step for future implementation. METHODS: We did a phase 3B open-label extension trial of the DVR (MTN-025/HIV Open-label Prevention Extension [HOPE]). Women who were HIV-1-negative and had participated in the MTN-020/ASPIRE phase 3 trial were offered 12 months of access to the DVR at 14 clinical research centres in Malawi, South Africa, Uganda, and Zimbabwe. At each visit (monthly for 3 months, then once every 3 months), women chose whether or not to accept the offer of the ring. Used, returned rings were tested for residual amounts of dapivirine as a surrogate marker for adherence. HIV-1 serological testing was done at each visit. Dapivirine amounts in returned rings and HIV-1 incidence were compared with data from the ASPIRE trial, and safety was assessed. This study is registered with ClinicalTrials.gov, NCT02858037. FINDINGS: Between July 16, 2016, and Oct 10, 2018, of 1756 women assessed for eligibility, 1456 were enrolled and participated in the study. Median age was 31 years (IQR 27-37). At baseline, 1342 (92·2%) women chose to take the DVR; ring acceptance was more than 79% at each visit up until 12 months and 936 (73·2%) of 1279 chose to take the ring at all visits. 12 530 (89·3%) of 14 034 returned rings had residual dapivirine amounts consistent with some use during the previous month (>0·9 mg released) and the mean dapivirine amount released was greater than in the ASPIRE trial (by 0·21 mg; p<0·0001). HIV-1 incidence was 2·7 per 100 person-years (95% CI 1·9-3·8, 35 infections), compared with an expected incidence of 4·4 per 100 person-years (3·2-5·8) among a population matched on age, site, and presence of a sexually transmitted infection from the placebo group of ASPIRE. No serious adverse events or grade 3 or higher adverse events observed were assessed as related to the DVR. INTERPRETATION: High uptake and persistent use in this open-label extension study support the DVR as an HIV-1 prevention option for women. With an increasing number of HIV-1 prophylaxis choices on the horizon, these results suggest that the DVR will be an acceptable and practical option for women in Africa. FUNDING: The Microbicide Trials Network and the National Institute of Allergy and Infectious Diseases, The Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health, all components of the US National Institutes of Health.
BACKGROUND: Two phase 3 clinical trials showed that use of a monthly vaginal ring containing 25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by approximately 30% compared with placebo. We aimed to evaluate use and safety of the dapivirine vaginal ring (DVR) in open-label settings with high background rates of HIV-1 infection, an important step for future implementation. METHODS: We did a phase 3B open-label extension trial of the DVR (MTN-025/HIV Open-label Prevention Extension [HOPE]). Women who were HIV-1-negative and had participated in the MTN-020/ASPIRE phase 3 trial were offered 12 months of access to the DVR at 14 clinical research centres in Malawi, South Africa, Uganda, and Zimbabwe. At each visit (monthly for 3 months, then once every 3 months), women chose whether or not to accept the offer of the ring. Used, returned rings were tested for residual amounts of dapivirine as a surrogate marker for adherence. HIV-1 serological testing was done at each visit. Dapivirine amounts in returned rings and HIV-1 incidence were compared with data from the ASPIRE trial, and safety was assessed. This study is registered with ClinicalTrials.gov, NCT02858037. FINDINGS: Between July 16, 2016, and Oct 10, 2018, of 1756 women assessed for eligibility, 1456 were enrolled and participated in the study. Median age was 31 years (IQR 27-37). At baseline, 1342 (92·2%) women chose to take the DVR; ring acceptance was more than 79% at each visit up until 12 months and 936 (73·2%) of 1279 chose to take the ring at all visits. 12 530 (89·3%) of 14 034 returned rings had residual dapivirine amounts consistent with some use during the previous month (>0·9 mg released) and the mean dapivirine amount released was greater than in the ASPIRE trial (by 0·21 mg; p<0·0001). HIV-1 incidence was 2·7 per 100 person-years (95% CI 1·9-3·8, 35 infections), compared with an expected incidence of 4·4 per 100 person-years (3·2-5·8) among a population matched on age, site, and presence of a sexually transmitted infection from the placebo group of ASPIRE. No serious adverse events or grade 3 or higher adverse events observed were assessed as related to the DVR. INTERPRETATION: High uptake and persistent use in this open-label extension study support the DVR as an HIV-1 prevention option for women. With an increasing number of HIV-1 prophylaxis choices on the horizon, these results suggest that the DVR will be an acceptable and practical option for women in Africa. FUNDING: The Microbicide Trials Network and the National Institute of Allergy and Infectious Diseases, The Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health, all components of the US National Institutes of Health.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Nelly R Mugo; Patrick Ndase; Katherine K Thomas; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Lara Kidoguchi; Robert W Coombs; Craig Hendrix; Mark A Marzinke; Lisa Frenkel; Jessica E Haberer; David Bangsberg; Connie Celum Journal: Lancet Infect Dis Date: 2014-10-07 Impact factor: 25.071
Authors: Deborah Donnell; Jared M Baeten; Namandjé N Bumpus; Justin Brantley; David R Bangsberg; Jessica E Haberer; Andrew Mujugira; Nelly Mugo; Patrick Ndase; Craig Hendrix; Connie Celum Journal: J Acquir Immune Defic Syndr Date: 2014-07-01 Impact factor: 3.731
Authors: Connie L Celum; Sinead Delany-Moretlwe; Jared M Baeten; Ariane van der Straten; Sybil Hosek; Elizabeth A Bukusi; Margaret McConnell; Ruanne V Barnabas; Linda-Gail Bekker Journal: J Int AIDS Soc Date: 2019-07 Impact factor: 5.396
Authors: Elizabeth T Montgomery; Mags Beksinska; Nyaradzo Mgodi; Jill Schwartz; Rachel Weinrib; Erica N Browne; Nonhlanhla Mphili; Petina Musara; Manjeetha Jaggernath; Susan Ju; Jenni Smit; Z Mike Chirenje; Gustavo F Doncel; Ariane van der Straten Journal: J Int AIDS Soc Date: 2019-05 Impact factor: 5.396
Authors: Robert J Schieffer; Ewa Bryndza Tfaily; Richard D'Aquila; George J Greene; Alex Carballo-Diéguez; Rebecca Giguere; Christine Tagliaferri Rael; Patrick F Kiser; Thomas J Hope Journal: AIDS Res Hum Retroviruses Date: 2021-12-28 Impact factor: 2.205
Authors: Dvora L Joseph Davey; Linda-Gail Bekker; Elizabeth A Bukusi; Benjamin H Chi; Sinead Delany-Moretlwe; Ameena Goga; Anne Drapkin Lyerly; Nyaradzo M Mgodi; Nelly Mugo; Landon Myer; Lisa M Noguchi; Lynda Stranix-Chibanda; Catherine Slack; Jillian Pintye Journal: Lancet HIV Date: 2022-01-25 Impact factor: 16.070
Authors: Kathleen Ridgeway; Elizabeth T Montgomery; Kevin Smith; Kristine Torjesen; Ariane van der Straten; Sharon L Achilles; Jennifer B Griffin Journal: Contraception Date: 2021-10-10 Impact factor: 3.051
Authors: Margaret W Gichane; Ariana W K Katz; Kenneth Ngure; Rachel Scheckter; Kubashni Woeber; Krishnaveni Reddy; Thelma Tauya; Chifundo Zimba; Juliane Etima; Nomvuyo Mangxilana; Thesla Palanee-Phillips; Ariane van der Straten Journal: AIDS Behav Date: 2021-05-19
Authors: Ariana W K Katz; Leila E Mansoor; Mercy Tsidya; Florence Mathebula; Devika Singh; Samantha Siva; Carolyne Akello; Tinei H Chitowa; Morgan Garcia; Lydia Soto-Torres; Elizabeth T Montgomery Journal: AIDS Behav Date: 2021-06-28